Citation Impact
Citing Papers
Molecular Analysis of Commensal Host-Microbial Relationships in the Intestine
2001 StandoutScience
Estimation of inhibitory quotient using a comparative equilibrium dialysis assay for prediction of viral response to hepatitis C virus inhibitors
2010
Regulation of microRNA function in animals
2018 Standout
Relative Contribution of CYP3A to Amitriptyline Clearance in Humans: In Vitro and In Vivo Studies
2001
Apparent Mechanism-based Inhibition of Human CYP2D6 in Vitro by Paroxetine: Comparison with Fluoxetine and Quinidine
2003
Effects of Acid‐Reducing Agents on the Pharmacokinetics of Lopinavir/Ritonavir and Ritonavir‐Boosted Atazanavir
2008
Therapeutic potential of resveratrol: the in vivo evidence
2006 Standout
The influence of drug-like concepts on decision-making in medicinal chemistry
2007 Standout
Effects of the Antifungal Agents on Oxidative Drug Metabolism
2000
Interactions of Herbs with Cytochrome P450
2003
Sedation Confounds Outcome Prediction in Cardiac Arrest Survivors Treated with Hypothermia
2010
Atazanavir plus low-dose ritonavir in pregnancy: pharmacokinetics and placental transfer
2007
Adherence to prescribed antihypertensive drug treatments: longitudinal study of electronically compiled dosing histories
2008
The potential environmental impact of engineered nanomaterials
2003 Standout
Cytochrome P-450 Polymorphisms and Response to Clopidogrel
2008 Standout
HIV drug development: the next 25 years
2007
Class-Sparing Regimens for Initial Treatment of HIV-1 Infection
2008
Clinical management of tuberculosis and HIV-1 co-infection
2010
Hepatitis C
2015
Therapeutic drug monitoring of lopinavir/ritonavir in pregnancy
2010
Rapid translocation of nanoparticles from the lung airspaces to the body
2010 StandoutNobel
Emergency Hospitalizations for Adverse Drug Events in Older Americans
2011 Standout
A Once-Daily Lopinavir/Ritonavir-Based Regimen Is Noninferior to Twice-Daily Dosing and Results in Similar Safety and Tolerability in Antiretroviral-Naive Subjects Through 48 Weeks
2009
Effects of genetic variants of human P450 oxidoreductase on catalysis by CYP2D6 in vitro
2010
Determinants of patient adherence: a review of systematic reviews
2013
Better Adherence with Once‐Daily Antiretroviral Regimens: A Meta‐Analysis
2009
Influence of cytochrome P450 polymorphisms on drug therapies: Pharmacogenetic, pharmacoepigenetic and clinical aspects
2007
Diagnosis, management, and treatment of hepatitis C: An update # † ‡
2008 Standout
Clinical Pharmacokinetic and Pharmacodynamic Profile of the HIV Integrase Inhibitor Elvitegravir
2011
Diagnosis and Treatment of Polycystic Ovary Syndrome: An Endocrine Society Clinical Practice Guideline
2013 Standout
Incidence of Resistance in a Double‐Blind Study Comparing Lopinavir/Ritonavir Plus Stavudine and Lamivudine to Nelfinavir plus Stavudine and Lamivudine
2004
Mechanism-Based Inhibition of Cytochrome P450 3A4 by Therapeutic Drugs
2005
Targeting multidrug resistance in cancer
2006 Standout
Allergic Rhinitis and Its Impact on Asthma
2001 Standout
Hepatitis C virus infection
2017
Cytochrome P450 Substrate Specificities, Substrate Structural Templates and Enzyme Active Site Geometries
1999
Inhibitory Effects of Silibinin on Cytochrome P‐450 Enzymes in Human Liver Microsomes
2000
Pulmonary Drug Delivery Systems: Recent Developments and Prospects;
2002
Pharmacokinetic-Pharmacodynamic Crisis in the Elderly
2006
Tuberculosis control and elimination 2010–50: cure, care, and social development
2010 Standout
Declining incidence of AIDS-defining opportunistic illnesses
2012
Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression
2001 Standout
How were new medicines discovered?
2011 Standout
Ontogeny of Hepatic and Renal Systemic Clearance Pathways in Infants
2002
The challenge of emerging and re-emerging infectious diseases
2004 StandoutNature
Lopinavir/Ritonavir
2003
Interindividual Differences in Hepatic Expression of CYP3A4: Relationship to Genetic Polymorphism in the 5′-Upstream Regulatory Region
1999
Identification and Assessment of Adherence-Enhancing Interventions in Studies Assessing Medication Adherence Through Electronically Compiled Drug Dosing Histories: A Systematic Literature Review and Meta-Analysis
2013
Polymorphic human cytochrome P450 enzymes: an opportunity for individualized drug treatment
1999
Microtubule-binding agents: a dynamic field of cancer therapeutics
2010 Standout
PROTAC targeted protein degraders: the past is prologue
2022 Standout
Comparative therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, and interferon beta against MERS-CoV
2020 Standout
Functional Genomic Analysis of C. elegans Molting
2005 StandoutNobel
Effect of short‐term administration of garlic supplements on single‐dose ritonavir pharmacokinetics in healthy volunteers
2003
Treatment for Adult HIV Infection
2004
Antiretroviral Treatment for Adult HIV Infection in 2002
2002
Effects of ginseng components on c-DNA-expressed cytochrome P450 enzyme catalytic activity
1999
Rapid Molecular Detection of Tuberculosis and Rifampin Resistance
2010 Standout
SwissADME: a free web tool to evaluate pharmacokinetics, drug-likeness and medicinal chemistry friendliness of small molecules
2017 Standout
Midazolam and Other Benzodiazepines
2008
Herb-Drug Interactions
2005 Standout
How to Manage Individualized Drug Therapy: Application of Pharmacogenetic Knowledge of Drug Metabolism and Transport
2000
Effects of herbal components on cDNA-expressed cytochrome P450 enzyme catalytic activity
2002
Cobicistat Versus Ritonavir as a Pharmacoenhancer of Atazanavir Plus Emtricitabine/Tenofovir Disoproxil Fumarate in Treatment-Naive HIV Type 1–Infected Patients: Week 48 Results
2013
Antiretroviral Treatment of Adult HIV Infection
2012 Standout
Opportunities and Challenges for HIV Care in Overlapping HIV and TB Epidemics
2008
Pyrazinamide clearance is impaired among HIV/tuberculosis patients with high levels of systemic immune activation
2017 StandoutNobel
St John's Wort increases expression of P‐glycoprotein: Implications for drug interactions
2002
Ontogeny of Hepatic and Renal Systemic Clearance Pathways in Infants
2002
The impact of cytokines on the expression of drug transporters, cytochrome P450 enzymes and chemokine receptors in human PBMC
2009
Functional expression and characterization of the envelope glycoprotein E1E2 heterodimer of hepatitis C virus
2019 StandoutNobel
Lopinavir/ritonavir exposure in treatment-naive HIV-infected children following twice or once daily administration
2006
Global tuberculosis drug development pipeline: the need and the reality
2010
Oral Druggable Space beyond the Rule of 5: Insights from Drugs and Clinical Candidates
2014
Guidelines for Using Antiretroviral Agents among HIV-Infected Adults and Adolescents: The Panel on Clinical Practices for Treatment of HIV*
2002
The Cochrane Collaboration's tool for assessing risk of bias in randomised trials
2011 Standout
Developmental Pharmacology — Drug Disposition, Action, and Therapy in Infants and Children
2003 Standout
Current race in the development of DAAs (direct-acting antivirals) against HCV
2014
Pharmacogenetics of P450 oxidoreductase: effect of sequence variants on activities of CYP1A2 and CYP2C19
2008
A Mechanistic Approach to Antiepileptic Drug Interactions
1998
Homology Modeling of Rat and Human Cytochrome P450 2D (CYP2D) Isoforms and Computational Rationalization of Experimental Ligand-Binding Specificities
2002
Therapeutic drug monitoring of antiretrovirals for people with HIV
2009
Plasma Levels, Safety, and 60-Week Efficacy of a Once-Daily Double-Boosted Protease Inhibitor Regimen of Atazanavir, Saquinavir, and Ritonavir
2008
pkCSM: Predicting Small-Molecule Pharmacokinetic and Toxicity Properties Using Graph-Based Signatures
2015 Standout
Analysis of the Structural Diversity, Substitution Patterns, and Frequency of Nitrogen Heterocycles among U.S. FDA Approved Pharmaceuticals
2014 Standout
Efficient Differentiation of Functional Hepatocytes from Human Embryonic Stem Cells
2008
Raltegravir-Based HAART Regimen in a Patient with Large B-Cell Lymphoma
2009
IN VITRO AND IN VIVO DRUG INTERACTIONS INVOLVING HUMAN CYP3A
1998
Docking and scoring in virtual screening for drug discovery: methods and applications
2004 Standout
Next Generation of Fluorine-Containing Pharmaceuticals, Compounds Currently in Phase II–III Clinical Trials of Major Pharmaceutical Companies: New Structural Trends and Therapeutic Areas
2016 Standout
An N-Terminal Amphipathic Helix in Hepatitis C Virus (HCV) NS4B Mediates Membrane Association, Correct Localization of Replication Complex Proteins, and HCV RNA Replication
2004 StandoutNobel
A Recombinant Hepatitis C Virus Genotype 1a E1/E2 Envelope Glycoprotein Vaccine Elicits Antibodies That Differentially Neutralize Closely Related 2a Strains through Interactions of the N-Terminal Hypervariable Region 1 of E2 with Scavenger Receptor B1
2019 StandoutNobel
Practice Guidelines for the Diagnosis and Management of Aspergillosis: 2016 Update by the Infectious Diseases Society of America
2016 Standout
The Molecular Biology, Biochemistry, and Physiology of Human Steroidogenesis and Its Disorders
2011 Standout
Clinical Practice Guideline for the Management of Candidiasis: 2016 Update by the Infectious Diseases Society of America
2015 Standout
U.S. Medical Eligibility Criteria for Contraceptive Use, 2016
2016 Standout
Donor-dependent variations in hepatic differentiation from human-induced pluripotent stem cells
2012 StandoutNobel
Interventions for enhancing medication adherence
2014 Standout
The Immune Response in Tuberculosis
2013 Standout
ADME/PK as part of a rational approach to drug discovery
2000
Generation of a Set of Simple, Interpretable ADMET Rules of Thumb
2008
Pharmacokinetic Interactions of Drugs with St John’s Wort
2004
ETCM: an encyclopaedia of traditional Chinese medicine
2018 Standout
The Combinatorial Synthesis of Bicyclic Privileged Structures or Privileged Substructures
2003 Standout
Evaluation of analytical and clinical performance of a dual-probe phenotyping method for CYP2D6 polymorphism and CYP3A4 activity screening.
2000
Part 8: Post–Cardiac Arrest Care
2015 Standout
Escape from Flatland: Increasing Saturation as an Approach to Improving Clinical Success
2009 Standout
Viral persistence, liver disease, and host response in a hepatitis C–like virus rat model
2017 StandoutNobel
Efficient Differentiation of Hepatocytes from Human Embryonic Stem Cells Exhibiting Markers Recapitulating Liver Development In Vivo
2008
ADMETlab 2.0: an integrated online platform for accurate and comprehensive predictions of ADMET properties
2021 Standout
Perspectives on HCV: Current Therapeutic Regimens and Drug–Drug Interactions
2017
Narrative Review: The Promotion of Gabapentin: An Analysis of Internal Industry Documents
2006 Standout
A Bioavailability Score
2005
Herbal Modulation of P‐Glycoprotein
2004
Applications of Fluorine in Medicinal Chemistry
2015 Standout
Medication Adherence
2009 Standout
Structure and Chemistry of Cytochrome P450
2005 Standout
Works of Richard Bertz being referenced
Effect of Rifampin on Steady-State Pharmacokinetics of Atazanavir with Ritonavir in Healthy Volunteers
2006
Protein Binding in Antiretroviral Therapies
2003
Alprazolam in Young and Elderly Men: Sensitivity and Tolerance to Psychomotor, Sedative and Memory Effects
1997
Hepatotoxicity and Gastrointestinal Intolerance When Healthy Volunteers Taking Rifampin Add Twice-Daily Atazanavir and Ritonavir
2009
Successful Projection of the Time Course of Drug Concentration in Plasma During a 1‐Year Period From Electronically Compiled Dosing‐Time Data Used as Input to Individually Parameterized Pharmacokinetic Models
2005
Ritonavir
1998
Pulmonary delivery of a dopamine D-1 agonist, ABT-431, in dogs and humans
1999
ABT-378/ritonavir plus stavudine and lamivudine for the treatment of antiretroviral-naive adults with HIV-1 infection: 48-week results
2001
The Effect of Ritonavir on the Pharmacokinetics of Meperidine and Normeperidine
2000
Coadministration of Lopinavir/Ritonavir and Phenytoin Results in Two-Way Drug Interaction Through Cytochrome P-450 Induction
2004
Once‐Daily versus Twice‐Daily Lopinavir/Ritonavir in Antiretroviral‐Naive HIV‐Positive Patients: A 48‐Week Randomized Clinical Trial
2004
Use of In Vitro and In Vivo Data to Estimate the Likelihood of Metabolic Pharmacokinetic Interactions
1997
Forty-eight-week evaluation of lopinavir/ritonavir, a new protease inhibitor, in human immunodeficiency virus-infected children
2003
Evaluation of drug‐drug interaction between daclatasvir and methadone or buprenorphine/naloxone
2014
Effect of Concomitantly Administered Rifampin on the Pharmacokinetics and Safety of Atazanavir Administered Twice Daily
2007
Pharmacokinetic-Pharmacodynamic Analysis of Lopinavir-Ritonavir in Combination with Efavirenz and Two Nucleoside Reverse Transcriptase Inhibitors in Extensively Pretreated Human Immunodeficiency Virus-Infected Patients
2002
The Effect of Renal Impairment on Single-Dose Pharmacokinetics of Daclatasvir, an HCV NS5A Inhibitor
2014
Assessment of Pharmacokinetic Interactions of the HCV Ns5A Replication Complex Inhibitor Daclatasvir with Antiretroviral Agents: Ritonavir-Boosted Atazanavir, Efavirenz and Tenofovir
2013
Estimation of Serum-Free 50-Percent Inhibitory Concentrations for Human Immunodeficiency Virus Protease Inhibitors Lopinavir and Ritonavir
2004
The Effect of Atazanavir/Ritonavir on the Pharmacokinetics of An Oral Contraceptive Containing Ethinyl Estradiol and Norgestimate in Healthy Women
2010
The Effect of Efavirenz on the Pharmacokinetics of An Oral Contraceptive Containing Ethinyl Estradiol and Norgestimate in Healthy HIV-Negative Women
2010
Pharmacokinetics of Adjusted-Dose Lopinavir-Ritonavir Combined with Rifampin in Healthy Volunteers
2004